Showing results (231-240 of 297) with videos related to

Sort By:
Pageof 30
American Journal of Hematology|April 10, 2019
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk diseaseAndrés E Quesada, Mark J Routbort, Courtney D DiNardo, et al.
Hemasphere|February 16, 2026
Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapiesJayastu Senapati, Jennifer Croden, Guillermo Garcia-Manero, et al.
British Journal of Haematology|March 30, 2019
Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatmentsBoyu Hu, Keyur P Patel, Hsiang-Chun Chen, et al.
Blood|June 11, 2021
Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemiaTomoyuki Tanaka, Kiyomi Morita, Sanam Loghavi, et al.
Blood Advances|April 22, 2021
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclaxCurtis A Lachowiez, Sanam Loghavi, Ken Furudate, et al.
Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Archives of Pathology & Laboratory Medicine|March 9, 2025
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/NeoplasmsSavanah D Gisriel, Fnu Aakash, John M Bennett, et al.
American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Blood Advances|August 16, 2022
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeCourtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.
Pageof 30